SavedAdd your journal

Journals / Annals of Medical Research / 2021 / Cilt: 28 - Sayı: 9

Retrospective evaluation of sarcoidosis cases: 10 years of experience from Turkey

Habibe Hezer
Aysegul Karalezli
Emine Arguder
Canan Hasanoglu
Hatice Kilic
Ebru Parlak
Mukremin Er
Serpil Kus
Hulya Erguden
Pages
1683–1689
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The mean age at diagnosis was 50.18 ± 13.73 years in all patients, while female patients’ mean age was 52.86 ± 13.06, male patients’ was 43.66 ± 13.24 (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Clinical features in sarcoidosis are very variable and can present with numerous phenotypes depending on organ involvements, clinical onset (acute, subacute, and chronic) and response to therapy.
📊
Key Findings & Data:In this study, we aimed to evaluate the clinical findings, diagnostic methods and treatments of patients with sarcoidosis by 10-years data in our hospital in Turkey.
💡
Conclusion & Impact:The mean age at diagnosis was 50.18 ± 13.73 years in all patients, while female patients’ mean age was 52.86 ± 13.06, male patients’ was 43.66 ± 13.24 (p
🔬Design:Research Article
📍Scope:2018 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: Clinical features in sarcoidosis are very variable and can present with numerous phenotypes depending on organ involvements, clinical onset (acute, subacute, and chronic) and response to therapy. In this study, we aimed to evaluate the clinical findings, diagnostic methods and treatments of patients with sarcoidosis by 10-years data in our hospital in Turkey. Materials and Methods: The study was carried out between January 2018 and January 2019. The patients were screened retrospectively from the hospital information system. Clinical details were collected using a structured data collection form. Results: 172 patients were included in our study. 122 (70.9%) were female and 50 (29.1%) were male. The mean age at diagnosis was 50.18 ± 13.73 years in all patients, while female patients’ mean age was 52.86 ± 13.06, male patients’ was 43.66 ± 13.24 (p

🔖

Cite This Article

Hezer, H., Karalezli, A., Arguder, E., Hasanoglu, C., Kilic, H., Parlak, E., Er, M., Kus, S., Erguden, H. (2022). Retrospective evaluation of sarcoidosis cases: 10 years of experience from Turkey. Annals of Medical Research, Cilt: 28 - Sayı: 9, 1683–1689. https://ajindex.com/articles/445914

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Ramachandraiah V, Aronow W, Chandy D. Pulmonary sarcoidosis: an update. Postgrad Med 2017;129:149- 58
  2. Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc 2013;10:362-70
  3. Rybicki BA, Major M, Popovich J Jr, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997;145:234-41
  4. Prasse A. The Diagnosis, Differential Diagnosis, and Treatment of Sarcoidosis. Dtsch Arztebl Int 2016;113:565-74
  5. Arkema EV, Grunewald J, Kullberg S, et al. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J 2016;48:1690-9
  6. Baughman RP, Field S, Costabel U, et al. Sarcoidosis in America. Analysis Based on Health Care Use. Ann Am Thorac Soc 2016;13:1244-52
  7. Musellim B, Kumbasar OO, Ongen G, et al. Epidemiological features of Turkish patients with sarcoidosis. Respir Med 2009;103:907-12
  8. Freemer M, King TE Jr. The ACCESS study: characterization of sarcoidosis in the United States. Am J Respir Crit Care Med 2001;164:1754-5
  9. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011;183:573-81
  10. Patterson KC, Chen ES. The Pathogenesis of Pulmonary Sarcoidosis and Implications for Treatment. Chest 2018;153:1432-42
  11. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J 1961;2:1165-72
  12. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736-55
  13. Gurkan OU, Celik G, Kumbasar O, et al. Sarcoidosis in Turkey: 1954-2000. Ann Saudi Med 2004;24:36-9
  14. Design of a case control etiologic study of sarcoidosis (ACCESS). ACCESS Research Group. J Clin Epidemiol 1999;52:1173-86
  15. Arkema EV, Cozier YC. Epidemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic Dis 2018;9:227-40
  16. Beghè D, Dall'Asta L, Garavelli C, et al. Sarcoidosis in an Italian province. Prevalence and environmental risk factors. PLoS One. 2017;12:e0176859
  17. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007;357:2153-65
  18. Valeyre D, Prasse A, Nunes H, et al. Sarcoidosis. Lanc